Sphingosine-1-phosphate signaling: a novel target for simultaneous adjuvant treatment of triple negative breast cancer and chemotherapy-induced neuropathic pain
Triple-negative breast cancer (TNBC) is very aggressive with high metastatic and mortality
rates and unfortunately, except for chemotherapy, there are few therapeutic options. The
bioactive sphingolipid metabolite sphingosine-1-phosphate (S1P) regulates numerous
processes important for cancer progression, metastasis, and neuropathic pain. The pro-drug
FTY720 (fingolimod, Gilenya) used to treat multiple sclerosis is phosphorylated in the body
to a S1P mimic that binds to S1PRs, except S1PR2, and also acts as a functional antagonist …
rates and unfortunately, except for chemotherapy, there are few therapeutic options. The
bioactive sphingolipid metabolite sphingosine-1-phosphate (S1P) regulates numerous
processes important for cancer progression, metastasis, and neuropathic pain. The pro-drug
FTY720 (fingolimod, Gilenya) used to treat multiple sclerosis is phosphorylated in the body
to a S1P mimic that binds to S1PRs, except S1PR2, and also acts as a functional antagonist …
